Endometrial Cancer
Conditions
Brief summary
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Detailed description
This study is being done in order to find out if this new approach is better or worse than the usual approach for early-stage endometrial cancer. The usual approach is defined as the care most people get for early-stage endometrial cancer. The usual approach for patients who are not in a study is treatment with surgery. Tissue that is removed as part of this procedure is analyzed in the pathology laboratory to guide the doctor to decide whether or not additional treatment such as radiation and or chemotherapy should be recommended.
Interventions
RADIATIONVaginal brachytherapy
Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
RADIATIONAdjuvant radiotherapy (EBRT +/- brachytherapy)
Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
OTHERObservation
Observation
Sponsors
Canadian Cancer Trials Group
Canadian Cancer Clinical Trials Network
Australia New Zealand Gynaecological Oncology Group
Gustave Roussy, Cancer Campus, Grand Paris
Leiden University Medical Center
Mario Negri Gynecologic Oncology group (MaNGO)
NRG Oncology
Philipps University Marburg
University College, London
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery. * Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed. * Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Patients' age must be ≥ 18 years. * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. * Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language * Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre * Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy
Exclusion criteria
* Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis. * Prior pelvic radiation. * Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years. * Clinical evidence of distant metastasis as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan) * Patients with a documented positive surgical margin. * Patients with a documented positive peritoneal washings, if performed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Estimate the rate of isolated vaginal recurrence at 3 years | 3 years |
| Estimate the rate of para-aortic recurrence at 3 years | 3 years |
| Estimate the rate of distant metastasis at 3 years | 3 years |
| Estimate recurrence-free survival | 9 years |
| Estimate endometrial cancer-specific survival | 9 years |
| Estimate overall survival | 9 years |
| Describe the impact of molecular classification on fear of recurrence by Fear of Recurrence Inventory | 9 years |
Countries
Australia, Canada, France, Germany, Italy, Netherlands, New Zealand, Norway, United States
Contacts
CONTACTWendy Parulekar
STUDY_CHAIRKathy Han
University Health Network, Princess Margaret Hospital, Toronto ON Canada
STUDY_CHAIRJessica McAlpine
BCCA-Vancouver Cancer Centre, Vancouver BC Canada
Outcome results
None listed